Compugen (NASDAQ:CGEN) is scheduled to issue its quarterly earnings data before the market opens on Monday, May 20th. Analysts expect the company to announce earnings of ($0.17) per share for the quarter.
Compugen (NASDAQ:CGEN) last posted its quarterly earnings data on Tuesday, February 26th. The biotechnology company reported ($0.16) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.21) by $0.05. On average, analysts expect Compugen to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.
NASDAQ CGEN opened at $3.46 on Friday. Compugen has a 12-month low of $2.00 and a 12-month high of $4.31. The company has a market capitalization of $177.46 million, a PE ratio of -8.44 and a beta of 2.43.
CGEN has been the topic of a number of recent research reports. Oppenheimer set a $9.00 price objective on shares of Compugen and gave the company a “buy” rating in a report on Tuesday, February 26th. Zacks Investment Research cut shares of Compugen from a “buy” rating to a “hold” rating in a research note on Tuesday, April 30th.
ILLEGAL ACTIVITY WARNING: “Compugen (CGEN) Scheduled to Post Quarterly Earnings on Monday” was first posted by Equities Focus and is owned by of Equities Focus. If you are reading this story on another publication, it was copied illegally and reposted in violation of international trademark & copyright law. The legal version of this story can be accessed at https://www.equitiesfocus.com/2019/05/18/compugen-cgen-scheduled-to-post-quarterly-earnings-on-monday.html.
Compugen Ltd., a therapeutic discovery company, engages in the research, development, and commercialization of therapeutic and product candidates in Israel and Europe. The company's therapeutic pipeline consists of immuno-oncology programs against novel drug targets in the areas of unmet medical needs in various cancer types and patient populations.
Featured Story: How prevalent are 12b-1 fees?
Receive News & Ratings for Compugen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Compugen and related companies with MarketBeat.com's FREE daily email newsletter.